Targeted treatments for advanced prostate cancer
Highly selective targeted theranostics for prostate cancers
This study is testing new treatments for men with high-risk localized prostate cancer that doesn't respond well to regular hormone therapies, aiming to make chemotherapy more effective while reducing side effects, so you can have better outcomes and a lower chance of the cancer coming back.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10899447 on NIH RePORTER |
What this research studies
This research focuses on developing highly selective therapies for patients with high-risk localized prostate cancer, which often becomes resistant to standard hormone treatments. The approach combines local and systemic therapies, utilizing antibody-drug conjugates to enhance the effectiveness of chemotherapy while minimizing side effects. By targeting cancer cells more precisely, the goal is to improve treatment outcomes and reduce the risk of tumor recurrence. Patients may be monitored for their response to these innovative therapies over the course of the study.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with high-risk localized prostate cancer who have not responded well to standard hormone therapies.
Not a fit: Patients with low-risk prostate cancer or those who have already undergone extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promising results with similar targeted therapies, indicating potential for success in this novel approach.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Basilion, James Peter — Case Western Reserve University
- Study coordinator: Basilion, James Peter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.